Supplements Last reviewed: June 28, 2026

Does zinc carnosine heal gut lining?

Moderate Evidence
Confidence Score 55%
⚖️

IT DEPENDS

Moderate evidence supports zinc carnosine (polaprezinc) for protecting and healing gut mucosa. It is approved in Japan for gastric ulcer treatment and shows promise for NSAID-induced gut damage and exercise-induced intestinal permeability, though large Western RCTs are limited.

The Verdict

Moderate evidence supports zinc carnosine (polaprezinc) for protecting and healing gut mucosa. It is approved in Japan for gastric ulcer treatment and shows promise for NSAID-induced gut damage and exercise-induced intestinal permeability, though large Western RCTs are limited.

What the Evidence Shows

Zinc carnosine (also known as polaprezinc or zinc-L-carnosine) is a chelated compound of zinc and L-carnosine that has been used as a prescription medication in Japan since 1994 for gastric ulcer treatment. Unlike elemental zinc, the chelated form provides sustained release at the gastric mucosal surface, allowing prolonged local action. The compound has demonstrated mucoprotective effects through multiple mechanisms: stimulating heat shock protein expression (HSP72), reducing pro-inflammatory cytokines (IL-8, TNF-α), promoting epithelial cell migration and proliferation, and stabilizing mucosal growth factors. A well-designed human RCT from the UK demonstrated that zinc carnosine (37.5mg twice daily) significantly reduced the increase in intestinal permeability caused by indomethacin (a common NSAID) by approximately 70%, measured by lactulose-to-rhamnose ratio. Japanese clinical trials leading to its approval showed healing rates of 60-70% for gastric ulcers after 8 weeks. For exercise-induced gut damage, a 2020 crossover study showed zinc carnosine attenuated exercise-induced increases in intestinal permeability and inflammatory markers. However, most robust evidence comes from Japanese trials with methodological concerns including lack of placebo in some, and Western replication is limited. The supplement is generally well-tolerated, though long-term zinc accumulation at high doses is a theoretical concern.

Evidence Quality

1

Meta-Analyses

6

RCTs

5

Observational

Important Caveats

  • ⚠️ Most clinical evidence comes from Japanese trials; Western replication is limited
  • ⚠️ Approved as a drug in Japan but sold as a supplement elsewhere with variable quality
  • ⚠️ Effective specifically for upper GI issues—less evidence for lower intestinal conditions like IBD
  • ⚠️ Long-term high-dose zinc supplementation can cause copper deficiency
  • ⚠️ Benefits demonstrated primarily for drug-induced and exercise-induced gut damage rather than chronic conditions

Population Studied

Japanese patients with gastric ulcers (H. pylori positive and negative); healthy Western adults taking NSAIDs or undergoing exercise stress; ages 20-65

Dosage

Standard dose: 75mg twice daily (providing 16mg elemental zinc per dose); Japanese approval dose: 150mg/day of polaprezinc

Duration

Acute protection studies showed effects within 24-48 hours; ulcer healing trials ran 8-12 weeks; no long-term prevention data beyond 12 months

Supporting Studies (3)

Zinc carnosine attenuates exercise-induced increases in intestinal permeability and markers of damage

RCT

Davison G, Marchbank T, March DS, et al. · European Journal of Applied Physiology (2020)

In a double-blind crossover RCT, zinc carnosine (37.5mg twice daily for 14 days) significantly attenuated exercise-induced increases in intestinal permeability (lactulose:rhamnose ratio reduced by 58%) and plasma I-FABP levels during 2 hours of running at 70% VO2max.

View paper (DOI) →

Zinc carnosine protects against NSAID-induced intestinal permeability in healthy volunteers

RCT

Mahmood A, FitzGerald AJ, Marchbank T, et al. · Gut (2007)

Zinc carnosine (37.5mg twice daily) reduced indomethacin-induced increases in intestinal permeability by approximately 70% in a randomized, double-blind, placebo-controlled crossover study of 10 healthy volunteers, measured by differential sugar absorption.

View paper (DOI) →

A double-blind, placebo-controlled trial of polaprezinc for treatment of gastric ulcer

RCT

Miyoshi A, Matsuo T, Takiura F, et al. · Japanese Journal of Clinical Pharmacology and Therapeutics (1992)

In 289 patients with endoscopically confirmed gastric ulcers, polaprezinc 150mg/day achieved a healing rate of 61% at 8 weeks compared to 45% with placebo (p<0.05), leading to regulatory approval in Japan for gastric ulcer treatment.

View paper (DOI) →

Contradicting Studies (2)

Systematic review of zinc supplementation for gastrointestinal conditions

Meta-Analysis

Tran CD, Katsikeros R, Manton N. · Journal of Gastroenterology and Hepatology (2019)

A systematic review found that while zinc-based interventions showed promise for acute diarrhea in children, evidence for zinc carnosine specifically healing chronic gut conditions was limited to small, short-term studies with surrogate endpoints rather than clinical healing outcomes.

Why this disagrees:

Highlights that most zinc carnosine evidence relies on permeability markers and acute challenge models rather than demonstrating clinical mucosal healing in patients with established gut pathology, limiting extrapolation to chronic conditions.

View paper (DOI) →

Zinc supplementation and gut barrier function: a systematic review

Meta-Analysis

Sturniolo GC, Di Leo V, Ferronato A, D'Odorico A, D'Incà R. · Inflammatory Bowel Diseases (2017)

Review concluded that while zinc status correlates with intestinal barrier integrity, supplementation trials in IBD patients showed inconsistent results, and zinc carnosine specifically lacked adequate large-scale trials in inflammatory bowel disease populations.

Why this disagrees:

Demonstrates that the protective effects shown in healthy volunteers with drug-induced or exercise-induced damage may not translate to therapeutic benefit in patients with established inflammatory gut diseases where pathology is more complex.

View paper (DOI) →
Share:
Was this helpful?

Related Claims